Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.
OPKO Completes Acquisition of Bio-Reference Laboratories.
OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD more »
OPKO Provides Update to Topline Data of Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults more »
OPKO'S GeneDx Extends Relationship with University of California Health for Genetic and Molecular Testing more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »